enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of “Buy” by Brokerages

enGene Holdings Inc. (NASDAQ:ENGN) has earned a consensus rating of “Buy” from the ten research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $25.22.

Several analysts have recently commented on the stock. Piper Sandler assumed coverage on shares of enGene in a research note on Tuesday, February 18th. They issued an “overweight” rating and a $26.00 target price for the company. JMP Securities reaffirmed a “market outperform” rating and issued a $18.00 price objective on shares of enGene in a report on Monday, December 23rd. HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of enGene in a research note on Tuesday, March 11th. Morgan Stanley reduced their price target on enGene from $37.00 to $34.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. Finally, UBS Group lowered enGene from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $34.00 to $7.00 in a report on Friday, February 14th.

enGene Price Performance

Shares of NASDAQ ENGN opened at $4.03 on Thursday. The stock has a fifty day moving average price of $5.42 and a 200 day moving average price of $6.82. enGene has a 1-year low of $3.78 and a 1-year high of $16.67. The company has a debt-to-equity ratio of 0.08, a current ratio of 16.87 and a quick ratio of 16.87. The company has a market cap of $205.44 million, a PE ratio of -6.95 and a beta of -0.38.

Hedge Funds Weigh In On enGene

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vontobel Holding Ltd. acquired a new position in shares of enGene during the fourth quarter worth $69,000. Jane Street Group LLC purchased a new stake in enGene during the 4th quarter worth $93,000. Toronto Dominion Bank purchased a new stake in enGene during the 4th quarter worth $97,000. Cubist Systematic Strategies LLC lifted its holdings in enGene by 15.7% in the 4th quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock worth $102,000 after buying an additional 2,080 shares in the last quarter. Finally, Corton Capital Inc. purchased a new position in enGene in the 4th quarter valued at about $157,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.